138
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Daratumumab-based regimen for cold agglutinin disease refractory to therapy directing B-cell clone

, , , , ORCID Icon &
Pages 410-412 | Received 02 Oct 2023, Accepted 19 Nov 2023, Published online: 29 Nov 2023
 

Author contributions

Kai-Ni Shen and Xin-Xin Cao contributed to the concept and design of the case report. Kai-Ni Shen and Dan-qing Zhao collected data and drafted the manuscript. Xin-Xin Cao aided in interpretation of clinical data and utilization of specialty specific clinical expertise to critically review and revise the manuscript. All authors critically revised the manuscript and approved the final version.

Informed consent

Written informed consent was obtained from the patient included in the study.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by the Beijing Natural Science Haidian frontier Foundation under Grant number L222081; the National High Level Hospital Clinical Research Funding under Grant number 2022-PUMCH-B-046; and the National High Level Hospital Clinical Research Funding under Grant number 2022-PUMCH-A-260.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.